FAQ on Clene Inc.'s Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS

What is the purpose of Clene Inc.’s neurofilament biomarker analysis for CNM-Au8(R)?

The analysis aims to validate the neuroprotective effects of CNM-Au8(R) in ALS patients, as shown in previous HEALEY Platform Trial results, and could support an accelerated approval submission for the drug later in 2025.

Why is the FDA’s feedback on Clene’s statistical analysis plan significant?

The FDA’s supportive feedback indicates a collaborative approach towards Clene’s research, potentially facilitating the path for CNM-Au8(R)’s approval by accepting the company’s revised statistical plan for the biomarker analysis.

How many ALS patients are participating in the NIH-sponsored Expanded Access Program for CNM-Au8?

Nearly 200 ALS patients are participating in the NIH-sponsored Expanded Access Program for CNM-Au8, where the drug is administered on a compassionate use basis.

When is Clene Inc. scheduled to conduct the neurofilament biomarker analysis?

Clene Inc. is set to conduct the neurofilament biomarker analysis early in the fourth quarter of 2025.

What are the implications of a positive outcome from the NfL assessment?

A positive outcome could strengthen Clene’s case for a new drug application submission under the accelerated approval pathway before the end of 2025, based on encouraging neuroprotective signals from the HEALEY ALS Platform Trial.

Who is Benjamin Greenberg, and what did he say about the FDA’s feedback?

Benjamin Greenberg, MD, is the Head of Medical at Clene. He described the FDA’s feedback as ‘constructive’ and mentioned the agency’s acceptance of Clene’s revised statistical plan is expected this summer.

What additional FDA meetings does Clene have scheduled in Q3 2025?

Clene has two additional FDA meetings scheduled in Q3 2025: one to review survival data from ALS patients receiving CNM-Au8 and another to discuss the company’s multiple sclerosis program and Phase 2 data from the VISIONARY-MS trial.

Where can I find more information about Clene Inc. and its research?

More information about Clene Inc. and its research can be found on their website (Clene (NASDAQ: CLNN)) and through the provided link to the FDA meeting details (https://ibn.fm/F5AHk).